Desta A Beyene1,2,3, Tammey J Naab2,4, Norma F Kanarek5, Victor Apprey6, Ashwini Esnakula2,4, Farahan A Khan2,4, Marc R Blackman1, Collis A Brown2,7, Tamaro S Hudson1,2,7. 1. Research Service, Veteran Affairs Medical Center, Washington, District of Columbia. 2. Howard University Cancer Center, Washington, District of Columbia. 3. Department of Biochemistry and Molecular Biology, Washington, District of Columbia. 4. Department of Pathology, College of Medicine, Washington, District of Columbia. 5. Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, and Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland. 6. National Human Genome Center, Howard University, Washington, District of Columbia. 7. Department of Pharmacology, College of Medicine, Washington, District of Columbia.
Abstract
BACKGROUND: Although studies have observed several markers correlate with progression of prostate cancer (PCa), no specific markers have been identified that accurately predict the progression of this disease, even in African American (AA) men who are generally at higher risk than other ethnic groups. The primary goal of this study was to explore whether three markers could predict the progression of PCa. METHOD: We investigated protein expression of Annexin 2 (ANX2), serine peptidase inhibitor, kazal type 1(SPINK1)/tumor-associated trypsin inhibitor (TATI), and heat shock protein 60 (Hsp60) in 79 archival human prostate trans-rectal ultrasound (TRUS) biopsy tissues according to a modified World Health Organization (WHO) classification: normal (WHO1a), Gleason Score (GS6 (WHO1b), GS7 subgroups (WHO2 = 3 + 4, WHO3 = 4 + 3), GS8 (WHO4), and GS9-10 (WHO5). AA men aged 41-90 diagnosed from 1990 to 2013 at Howard University were included. Automated staining assessed expression of each biomarker. Spearman correlation assessed the direction and relationship between biomarkers, WHO and modified WHO GS, age, and 5-year survival. A two-tailed t-test and ANOVA evaluated biomarkers expression in relationship to WHO normal and other GS levels, and between WHO GS levels. A logistic and linear regression analysis examined the relationship between biomarker score and WHO GS categories. Kaplan-Meier curves graphed survival. RESULTS: ANX2 expression decreased monotonically with the progression of PCa while expression of SPINK1/TATI and Hsp60 increased but had a more WHO GS-specific effect; SPINK1/TATI differed between normal and GS 2-6 and HSP60 differed between GS 7 and GS 2-6. WHO GS was found to be significantly and negatively associated with ANX2, and positively with SPINK1/TATI and Hsp60 expression. High SPINK1/TATI expression together with the low ANX2 expression at higher GS exhibited a bi-directional relationship that is associated with PCa progression and survival. CONCLUSION: Importantly, the data reveal that ANX2, and SPINK1/TAT1 highly associate with WHO GS and with the transition from one stage of PrCa to the next in AA men. Future research is needed in biracial and larger population studies to confirm this dynamic relationship between ANX2 and SPINK1 as independent predictors of PCa progression in all men.
BACKGROUND: Although studies have observed several markers correlate with progression of prostate cancer (PCa), no specific markers have been identified that accurately predict the progression of this disease, even in African American (AA) men who are generally at higher risk than other ethnic groups. The primary goal of this study was to explore whether three markers could predict the progression of PCa. METHOD: We investigated protein expression of Annexin 2 (ANX2), serine peptidase inhibitor, kazal type 1(SPINK1)/tumor-associated trypsin inhibitor (TATI), and heat shock protein 60 (Hsp60) in 79 archival human prostate trans-rectal ultrasound (TRUS) biopsy tissues according to a modified World Health Organization (WHO) classification: normal (WHO1a), Gleason Score (GS6 (WHO1b), GS7 subgroups (WHO2 = 3 + 4, WHO3 = 4 + 3), GS8 (WHO4), and GS9-10 (WHO5). AA men aged 41-90 diagnosed from 1990 to 2013 at Howard University were included. Automated staining assessed expression of each biomarker. Spearman correlation assessed the direction and relationship between biomarkers, WHO and modified WHO GS, age, and 5-year survival. A two-tailed t-test and ANOVA evaluated biomarkers expression in relationship to WHO normal and other GS levels, and between WHO GS levels. A logistic and linear regression analysis examined the relationship between biomarker score and WHO GS categories. Kaplan-Meier curves graphed survival. RESULTS:ANX2 expression decreased monotonically with the progression of PCa while expression of SPINK1/TATI and Hsp60 increased but had a more WHO GS-specific effect; SPINK1/TATI differed between normal and GS 2-6 and HSP60 differed between GS 7 and GS 2-6. WHO GS was found to be significantly and negatively associated with ANX2, and positively with SPINK1/TATI and Hsp60 expression. High SPINK1/TATI expression together with the low ANX2 expression at higher GS exhibited a bi-directional relationship that is associated with PCa progression and survival. CONCLUSION: Importantly, the data reveal that ANX2, and SPINK1/TAT1 highly associate with WHO GS and with the transition from one stage of PrCa to the next in AA men. Future research is needed in biracial and larger population studies to confirm this dynamic relationship between ANX2 and SPINK1 as independent predictors of PCa progression in all men.
Authors: Carolina Castilla; Belén Congregado; José M Conde; Rafael Medina; Francisco J Torrubia; Miguel A Japón; Carmen Sáez Journal: Urology Date: 2010-08-12 Impact factor: 2.649
Authors: Sven Perner; Matthias D Hofer; Robert Kim; Rajal B Shah; Haojie Li; Peter Möller; Richard E Hautmann; Juergen E Gschwend; Rainer Kuefer; Mark A Rubin Journal: Hum Pathol Date: 2007-02-22 Impact factor: 3.466
Authors: Kosj Yamoah; Michael H Johnson; Voleak Choeurng; Farzana A Faisal; Kasra Yousefi; Zaid Haddad; Ashley E Ross; Mohammed Alshalafa; Robert Den; Priti Lal; Michael Feldman; Adam P Dicker; Eric A Klein; Elai Davicioni; Timothy R Rebbeck; Edward M Schaeffer Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin Journal: Am J Surg Pathol Date: 2007-06 Impact factor: 6.394
Authors: C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick Journal: Br J Cancer Date: 2009-08-25 Impact factor: 7.640
Authors: Arielle Shkedi; Isabelle R Taylor; Frank Echtenkamp; Poornima Ramkumar; Mohamed Alshalalfa; Génesis M Rivera-Márquez; Michael A Moses; Hao Shao; Robert Jeffrey Karnes; Len Neckers; Felix Feng; Martin Kampmann; Jason E Gestwicki Journal: Cell Chem Biol Date: 2022-02-01 Impact factor: 8.116
Authors: Anne-Marie Ray; Nilshad Salim; Mckayla Stevens; Siddhi Chitre; Sanofar Abdeen; Alex Washburn; Jared Sivinski; Heather M O'Hagan; Eli Chapman; Steven M Johnson Journal: Bioorg Med Chem Date: 2021-04-19 Impact factor: 3.461